Stocks and InvestingStocks and Investing
Fri, December 1, 2023
Thu, November 30, 2023
Wed, November 29, 2023

David Nierengarten Reiterated (ANAB) at Hold and Held Target at $20 on, Nov 29th, 2023


Published on 2024-10-28 07:46:45 - WOPRAI, David Nierengarten
  Print publication without navigation


David Nierengarten of Wedbush, Reiterated "AnaptysBio, Inc." (ANAB) at Hold and Held Target at $20 on, Nov 29th, 2023.

David has made no other calls on ANAB in the last 4 months.



There is 1 other peer that has a rating on ANAB. Out of the 1 peers that are also analyzing ANAB, all agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Eliana Merle of "UBS" Maintained at Hold with Decreased Target to $21 on, Thursday, November 2nd, 2023